The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq listed BridgeBio Pharma, Inc. (BBIO) has revealed Month 12 topline results from the Phase 3 ATTRibute-CM study. Following the results, shares of the biopharmaceutical company crashed 72% on ...
The OLE study involves 330 participants who completed the 30-month ATTRibute-CM Phase 3 study. Key initial results from the OLE study show that continuous treatment with acoramidis led to: The OLE ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
BridgeBio (BBIO) Pharma presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was ...
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 ...
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio” or the "Company”), a new type of biopharmaceutical company focused on genetic diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results